Zobrazeno 1 - 10
of 151
pro vyhledávání: '"Jeong Eun Kim"'
Autor:
Myongjae Lee, In-Gyu Je, Jeong Eun Kim, Yeongran Yoo, Jong-Ha Lim, Eunhye Jang, Yoonsuk Lee, Dong Keun Song, An-Na Moon, Jeong-Ah Kim, Jinah Jeong, Joon-Tae Park, Jung Woo Lee, Ji-Hoon Yang, Chang-Hee Hong, Sun-Young Park, Young-Whan Park, Nam Seok Baek, Sungsook Lee, Kyoung Soo Ha, SungKu Choi, Won Sik Lee
Publikováno v:
Molecular Cancer Therapeutics. 22:333-342
PARP inhibitors have been approved by the FDA for use in the treatment of patients with ovarian, breast, pancreatic, and prostate cancers. PARP inhibitors show diverse suppressive effects on PARP family members and PARP-DNA trapping potency. These pr
Publikováno v:
Journal of Cancer. 14:1216-1222
Autor:
Jin-Hee Ahn, Hyo Song Kim, Young Suk Park, Jun Hyeong Lee, Kum-Hee Yun, Young Han Lee, Seung Hyun Kim, Tae Il Kim, Jeong Eun Kim, Se Hyun Kim, Kyu Sang Lee, Jeeyun Lee, Jung Kyoon Choi, Joonha Kwon
Publikováno v:
Cancer Research and Treatment. 54:1240-1255
Background: Desmoid tumor, also known as aggressive fibromatosis, is well-characterized by abnormal Wnt/β-catenin signaling. Various therapeutic options, including imatinib, are available to efficiently treat desmoid tumor. However, molecular mechan
Autor:
Kyunghye Bang, Jeong Eun Kim, Tae Won Kim, Sun Young Kim, Seok‐Byung Lim, In Ja Park, Chan Wook Kim, Yong Sik Yoon, Yong Sang Hong
Publikováno v:
Cancer Medicine. 12:2861-2868
Colorectal cancer with peritoneal metastasis (PM) has been considered a non-curative disease. PM is associated with reduced overall survival (OS) and worse prognosis compared with metastasis at other sites. We aimed to investigate the treatment outco
Publikováno v:
Cancer Medicine. 12:4679-4689
Primary central nervous system lymphoma (PCNSL) is an uncommon extranodal non-Hodgkin's lymphoma. Here, the feasibility of nuclear magnetic resonance (NMR) metabolomics for the diagnosis and prognosis prediction of PCNSL, as well as its correlation w
Autor:
Seockhoon Chung, Moon Jung Kwon, Su-Jin Koh, Seyoung Seo, So Hee Kim, Inn-Kyu Cho, Sang Min Yoon, Hee Jeong Kim, Kyumin Kim, Myung Hee Ahn, Hwa Jung Kim, Joohee Lee, Harin Kim, Jeong Eun Kim, Kiyoung Son
Publikováno v:
Cancer Research and Treatment. 54:671-679
Purpose Literature is scarce regarding cancer care utilization during the massive outbreak of coronavirus disease 2019 (COVID-19) in the Republic of Korea. We investigated functional impairments in mental health and their relationships with depressio
Publikováno v:
Cancer Research and Treatment. 54:469-477
Purpose In hormone receptor-positive, human epidermal growth factor receptor 2–negative metastatic breast cancer (HR+ HER2–MBC), the mainstay treatment options include cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and everolimus (EVE) in combi
Autor:
Ju Won Kim, Hee Kyung Ahn, Jong Gwon Choi, Yee Soo Chae, Gyeong-Won Lee, Keon Uk Park, Eunmi Lee, Sung Hoon Sim, Jee Hyun Kim, Yeon Hee Park, Miso Kim, Jin Hyun Park, Jeong Eun Kim, Han Jo Kim, Mi Sun Ahn, So Yeon Oh, Min Hwan Kim, Su-Jin Koh, Kyoung Eun Lee, Myoung Joo Kang, Jae Ho Byun, Joo Young Ha, Jung Hye Kwon, Joo Young Jung, Su Ee Lee, Inhae Park, Kyong Hwa Park
Publikováno v:
Cancer Research. 82:P5-16
Background: Prognosis of patients with HER-2 positive metastatic breast cancer (MBC) has been revolutionized with the development of monoclonal antibodies targeting HER-2 and antibody-drug conjugate, but resistance to anti-HER-2 therapy is inevitable
Autor:
Si Yeol Song, Min Hee Lee, Hyehyun Jeong, Jin-Hee Ahn, Hyeon-Su Im, Kyung-Ja Cho, Hye Won Chung, Jong Seok Lee, Joon Seon Song, Jeong Eun Kim, Wanlim Kim
Publikováno v:
Cancer Management and Research
Hyehyun Jeong,1,* Hyeon-Su Im,1,2,* Wanlim Kim,3 Jong-Seok Lee,3 Si Yeol Song,4 Joon Seon Song,5 Kyung-Ja Cho,5 Hye Won Chung,6 Min Hee Lee,6 Jeong Eun Kim,1,* Jin-Hee Ahn1,* 1Department of Oncology, Asan Medical Center, University of
Autor:
Kyu-Pyo Kim, Ji Sung Lee, Tae Won Kim, Jeong Eun Kim, Yong Sang Hong, Sun Young Kim, Yeong Hak Bang
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Scientific Reports
Scientific Reports
There is an unmet medical need for later-line treatment options for patients with metastatic colorectal cancer (mCRC). Considering that, beyond progression, co-treatment with bevacizumab and cytotoxic chemotherapy showed less toxicity and a significa